Shire recalls 39 lots of Daytrana due to design flaws

29 March 2009

UK drugmaker Shire has withdrawn 39 lots of Daytrana (methylphenidate transdermal system) for attention-deficit hyperactivity disorder because  some of the patches no longer meet their release liner removal  specification and, as a result, patients and caregivers could have  difficulties removing the liners.

Shire stressed that its action is not due to safety issues and noted  that Daytrana patches, including those in the lots withdrawn, can  continue to be used unless the release liner cannot be removed, or the  patches are damaged while being opened.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight